ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST
Read the rest here:
Inside information: Orion upgrades full-year outlook for 2024
Related Post
- Kraig Biocraft Laboratories Expands Facilities to Support Spider Silk Production Growth - July 2nd, 2024
- NeuroStar® Launches Better Me Provider Program Nationwide - July 2nd, 2024
- Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1... - July 2nd, 2024
- Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy - July 2nd, 2024
- Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene... - July 2nd, 2024
- Foxo Technologies, Inc., Regains Compliance with SEC Reporting Requirements - July 2nd, 2024
- Ricky Williams Applauds NCAA’s Decision to Remove Cannabinoids from Banned Substances List, Emphasizes Need for Education on Cannabis - July 2nd, 2024
- Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes - July 2nd, 2024
- GRI Bio to Present at the 8th Annual IPF Summit - July 2nd, 2024
- TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development... - July 2nd, 2024
- Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research... - July 2nd, 2024
- Protect Pharmaceutical Corp. Issues Corporate Update - July 2nd, 2024
- Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024 - July 2nd, 2024
- Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer - July 2nd, 2024
- A-S Medication Solutions Announces Strategic Transition - July 2nd, 2024
- HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV - July 2nd, 2024
- Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd. - July 2nd, 2024
- Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III... - July 2nd, 2024
- Alvotech Issues New Shares to Holders of Convertible Bonds - July 2nd, 2024
- I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 - May 24th, 2024
- BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology... - May 24th, 2024
- Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated... - May 24th, 2024
- NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of... - May 24th, 2024
- Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the... - May 24th, 2024
- FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with... - May 24th, 2024
- Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - May 24th, 2024
- Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 - May 24th, 2024
- G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting - May 24th, 2024
- Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting - May 24th, 2024
- Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 24th, 2024
- SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 24th, 2024
- Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024... - May 24th, 2024
- 3Daughters to Participate in Women’s Health Panel During the 2024 BIO International Convention in San Diego, CA, June 3-6 - May 24th, 2024
- Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at... - May 24th, 2024
- Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - May 24th, 2024
- HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting - May 24th, 2024
- Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting - May 24th, 2024
- Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 24th, 2024
- Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024 - May 24th, 2024
- Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - May 14th, 2024
- Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - May 14th, 2024
- Cardiff Oncology to Present at Upcoming Investor Conferences in May - May 14th, 2024
- scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference - May 14th, 2024
- Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results - May 14th, 2024
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 - May 14th, 2024
- PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock... - May 14th, 2024
- Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones - May 14th, 2024
- Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights - May 14th, 2024
- Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights - May 14th, 2024
- Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights - May 14th, 2024
- Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update - May 14th, 2024
- Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - May 14th, 2024
- Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update - May 14th, 2024
- Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock - May 14th, 2024
- HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory... - May 14th, 2024
- Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights - May 14th, 2024
- Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024 - May 14th, 2024
- Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update - May 14th, 2024
- HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in... - May 14th, 2024
- AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs - April 16th, 2024
- Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research... - April 16th, 2024
- Redemption Date Announced for Warrants - April 16th, 2024
- Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products - April 16th, 2024
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors - April 16th, 2024
- Publication Annual Report – Annual Shareholders' Meeting - April 16th, 2024
- Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American... - April 16th, 2024
- Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort - April 16th, 2024
- New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for... - April 16th, 2024
- Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million - April 16th, 2024
- ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC - April 16th, 2024
- Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders - April 16th, 2024
- GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents - April 16th, 2024
- TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation - April 16th, 2024
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - April 16th, 2024
- BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement - April 16th, 2024
- Faron Confirms Plans for the Coming Months Under New Leadership - April 16th, 2024
- Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 - April 16th, 2024
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease - April 16th, 2024
- Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 - April 16th, 2024
- Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® - March 18th, 2024
Tags: